LCA approach to the analysis of solvent waste issues in the pharmaceutical industry

被引:104
|
作者
Raymond, Michael J. [1 ]
Slater, C. Stewart [1 ]
Savelski, Mariano J. [1 ]
机构
[1] Rowan Univ, Dept Chem Engn, Glassboro, NJ 08028 USA
关键词
ENERGY;
D O I
10.1039/c003666h
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Life cycle assessment offers a unique opportunity to analyze emission reductions across all manufacturing sectors. However, few efforts have been made to apply this method to the pharmaceutical industry. Typically, between 80 and 90% of the total mass used in the production of an active pharmaceutical ingredient (API) may be attributed to solvent use. Manufacture of virgin solvent and solvent waste management contribute significantly more life cycle emissions than comparable processes for commodity chemicals, with the majority of this waste consisting of CO2 and other green house gas emissions. Three case studies from Pfizer, Bristol-Myers Squibb, and Novartis are examined. In these cases, solvent recovery and reduction techniques are integrated into API syntheses. It is shown that the actual extent of the environmental footprint reduction can only be realized with a full life cycle analysis.
引用
收藏
页码:1826 / 1834
页数:9
相关论文
共 50 条
  • [21] Research on management issues in the pharmaceutical industry: a literature review
    Narayana, Sushmita A
    Pati, Rupesh Kumar
    Vrat, Prem
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL AND HEALTHCARE MARKETING, 2012, 6 (04) : 351 - 375
  • [22] Case Study on Patent Issues in Indian Pharmaceutical Industry
    Sukumaran, A. K.
    Vijayabanu, C.
    Renganathan, R.
    Balachandran, C. A. S.
    RESEARCH JOURNAL OF PHARMACEUTICAL BIOLOGICAL AND CHEMICAL SCIENCES, 2016, 7 (01): : 1009 - 1015
  • [23] Pharmaceutical industry; India's concerns, issues and options
    Misra, Krishna
    NATIONAL ACADEMY SCIENCE LETTERS-INDIA, 2011, 34 (11-12): : 375 - 381
  • [24] Further statistical issues in project prioritization in the pharmaceutical industry
    Senn, S
    DRUG INFORMATION JOURNAL, 1998, 32 (01): : 253 - 259
  • [25] Intellectual Property Rights Issues in Indian Pharmaceutical Industry
    Bindusha, H. C.
    JOURNAL OF PHARMACEUTICAL RESEARCH INTERNATIONAL, 2021, 33 (38B) : 281 - 286
  • [26] CME and the pharmaceutical industry: Ethical issues, dilemmas and solutions
    Prior, N
    Evans, A
    Harrison, J
    Sara, G
    Scott, M
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2002, 36 (06): : A11 - A11
  • [27] ISSUES OF THE CORPORATE CARBON FOOTPRINT CALCULATION IN THE PHARMACEUTICAL INDUSTRY
    Baran, Jolanta
    ECOLOGY, ECONOMICS, EDUCATION AND LEGISLATION CONFERENCE PROCEEDINGS, SGEM 2016, VOL III, 2016, : 313 - 320
  • [28] Some statistical issues in project prioritization in the pharmaceutical industry
    Senn, S
    STATISTICS IN MEDICINE, 1996, 15 (24) : 2689 - 2702
  • [29] COMMERCIAL APPROACH OF PHARMACEUTICAL-INDUSTRY
    FRENCH, TA
    BRITISH MEDICAL JOURNAL, 1983, 287 (6405): : 1632 - 1632
  • [30] A product portfolio approach in the pharmaceutical industry
    Rotstein, GE
    Papageorgiou, LG
    Shah, N
    Murphy, DC
    Mustafa, R
    COMPUTERS & CHEMICAL ENGINEERING, 1999, 23 : S883 - S886